Weidinger S, Blauvelt A, Papp KA, Reich A, et al. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2024 Nov 8:S0091-6749(24)01175.
PMID: 39522654